Genomic drug development

Scientists worldwide know Gene Logic for compiling the largest and most detailed proprietary knowledgebase of gene expression profiles of human and animal tissues and cells. This expertise, combined with its industry-leading informatics capabilities is the foundation for Gene Logic's growing portfolio of innovative solutions that include gene expression and toxicogenomics databases, software tools, data generation, and professional services. These capabilities give it unique qualifications to help its clients make faster, better compound decisions.

Whether as an outsourcing partner for data generation, expert analysis and services or to enhance internal capabilities, Gene Logic offers solutions designed and scaled to meet technical and economic requirements, helping to saving time and money in the lengthy and costly drug development process. As a result of these partnerships, scientists are provided with answers to critical questions arising throughout the drug development process:

1) which target
2) which drug candidate
3) which patient.

Which target?

Successful implementation of biomarkers in drug development can accelerate development timelines, thus enabling earlier decision making and increasing the success of drug candidates in preclinical safety testing and clinical trials. Gene Logic systems enable the identification, prioritisation and confirmation of drug targets and biomarkers. The depth and breadth of gene expression data helps to identify the best biomarker candidates for target identification and drug development. Its analytical tools allow the selection of drug targets that display unique expression profiles with respect to human tissue type and disease indication. And, to help ensure success, Gene Logic scientists are available to provide in-depth, personal consultations.

Which drug candidate?

Gene Logic can augment the understanding and prioritisation of drug candidates based on their potential for human toxicity from predictive and mechanistic analyses. The resulting wealth of information allows for better informed drug development decisions, advancing the most promising candidates.

Which patient?

In clinical development, genomics data is applied to aid in patient stratification, helping identify those patients who may be best suited for, and more responsive to, particular drugs and therapies.

Providing solutions.

The market is exerting tremendous pressure on developers to produce safer, more effective drugs. This, along with shrinking research and development budgets, places urgency on fine-tuning and accelerating activities throughout the drug discovery and development processes. Gene Logic's growing portfolio of innovative solutions includes gene expression and toxicogenomics databases, software tools, data generation, and professional services. It provides application support for:

Drug target and biomarker discovery within and across species
Mechanism of disease and mechanism of action
Predictive toxicology
Investigative and mechanistic toxicology
Patient and drug indication selection

Different products for different needs.

With Genomics solutions, a Gene Logic partner has the ability to access the gene expression profiles of thousands of normal and diseased human and animal tissues in the key therapeutic areas of oncological, inflammatory, cardiovascular and central nervous system diseases, as well as metabolic disorders. Embedded in the genomics content is integrated biological pathway knowledge that provides a deeper understanding of the activity of cellular processes at the gene expression level. This knowledge allows one to adopt a systems biology approach to understanding disease mechanisms and to establish intellectual property.

Gene Logic's genomic solutions portfolio includes the BioExpress® database and disease-specific data suites for in-depth studies, the ASCENTA® and SCIANTIS™ systems for rapid, web-based gene expression analysis, and Microarray Data Generation and Analysis™ Services for quality results. Its toxicogenomics solutions include a variety of economical products and services that range from full ToxExpress® System subscriptions, ToxSuite™ data sets and web-based software solutions such as ToxShield™ Suites to professional services such as mechanism of toxicity reports and ToxScreen™ reports.

Gene Logic helps pharmaceutical and biotechnology companies as well as academic and government institutions accelerate drug development through a genomics and toxicogenomics solutions portfolio.

Further information

Gene Logic Inc.
Tel: +1 800 4363 5642
Fax: +1 301 987 1701
Email: info@genelogic.com
Website: www.genelogic.com

< Back to Drug Discovery index

< Back to Market Resources index